NEW YORK, August 19, 2026, 07:25 EDT
Moderna Inc. NASDAQ:MRNA jumped 57.27% before Wednesday’s open after its personalized cancer vaccine met two goals in a Phase 3 melanoma trial. The move pushed the shares to $99.02 from Tuesday’s $62.96 close.
The readout is the first positive late-stage result for an mRNA cancer vaccine. It moves Moderna’s oncology platform closer to a filing and reduces one of the company’s largest development risks.
The price response created a new valuation test. A preliminary estimate puts Moderna’s premarket equity value near $39.5 billion, up about $14.4 billion from Tuesday. The estimate uses 399.24 million shares outstanding and the indicated premarket price.
| Market snapshot | Moderna | Merck |
|---|---|---|
| Google Finance ticker | NASDAQ:MRNA | NYSE:MRK |
| August 18 close | $62.96 | $135.17 |
| August 19 premarket | $99.02 | $140.46 |
| Premarket change | +57.27% | +3.91% |
Merck & Co. Inc. NYSE:MRK and Moderna enrolled 1,137 patients with surgically removed stage IIB-IV melanoma. Intismeran plus Keytruda reduced recurrence and distant spread versus Keytruda alone. The trial remains ongoing, and the companies have not disclosed hazard ratios or survival data.
| Melanoma evidence | Phase 2b | Phase 3 interim |
|---|---|---|
| Trial | KEYNOTE-942 | INTerpath-001 |
| Patients | 157 | 1,137 |
| Primary endpoint | 49% lower recurrence/death risk at five years | Met; magnitude not disclosed |
| Key secondary endpoint | 59% lower distant metastasis/death risk | Met; magnitude not disclosed |
| Safety | Consistent with prior analyses | No new safety signals reported |
Intismeran is made for each patient from mutations found in that person’s tumor. It encodes as many as 34 neoantigens, aiming to train T cells against the cancer. Patients received up to nine doses alongside Keytruda for roughly one year.
The smaller study supplied durable support before Wednesday’s readout. At 60.3 months, recurrence or death risk fell 49%. Distant metastasis or death risk fell 59%. Moderna development chief David Berman said those findings supported the treatment’s “potential long-term benefit” in high-risk melanoma. Merck
That evidence still leaves important blanks. The Phase 3 effect size, confidence intervals and overall-survival trend will determine how regulators and physicians judge the combination. The companies plan a medical-meeting presentation and regulatory discussions.
Moderna’s balance sheet gives it room to prepare. The company held $6.9 billion in cash and investments at June 30. It then paid $950 million in July for a litigation settlement. Management expects $4.7 billion to $5.2 billion at year-end.
| Financial measure | Q2 2026 | Comparison |
|---|---|---|
| Revenue | $145 million | $142 million in Q2 2025 |
| GAAP net loss | $782 million | $825 million in Q2 2025 |
| GAAP loss per share | $1.97 | $2.13 in Q2 2025 |
| Cash and investments | $6.9 billion | $7.5 billion at March 31 |
| 2026 year-end cash outlook | $4.7-$5.2 billion | Raised about $0.2 billion |
Wednesday’s indicated price also outran every recent analyst target shown by Google Finance. The $99.02 quote stood 28.6% above Piper Sandler’s $77 high target. It was more than double the $48.92 average.
| Analyst | Firm | Recommendation | Target | Premarket price vs. target |
|---|---|---|---|---|
| Edward Tenthoff | Piper Sandler | Buy | $77 | +28.6% |
| Geoff Meacham | Citi | Hold | $60 | +65.0% |
| Eliana Merle | Barclays | Hold | $48 | +106.3% |
| Jessica Fye | J.P. Morgan | Sell | $40 | +147.6% |
| Terence Flynn | Morgan Stanley | Hold | $39 | +153.9% |
The 57% Moderna move versus Merck’s 4% gain shows where investors see the leverage. Keytruda is already a large product for Merck. Intismeran could reshape Moderna’s post-COVID revenue mix if approved.
Risks: The topline release lacks effect sizes, mature survival data and a regulatory timetable. Personalized manufacturing may also complicate cost, capacity and access. A weaker full dataset could reverse part of the premarket gain.
The next valuation reset will depend on the full Phase 3 curves. Until then, the market has priced in more than clinical success. It has priced in a faster oncology transition.
Related articles: NASDAQ:MRNA
Phase 3 win, valuation reset
August 19, 2026 · 07:25 EDT
U.S. premarket
Premarket reaction
INTerpath-001: what changed
Price versus recent analyst targets
Funding the oncology transition
| Metric | Value |
|---|---|
| Q2 revenue | $145M |
| Q2 GAAP net loss | $(782)M |
| June 30 cash & investments | $6.9B |
| July settlement payment | $(950)M |
| 2026 year-end cash guide | $4.7–5.2B |
